ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Monopar Therapeutics Inc

Monopar Therapeutics Inc (MNPR)

0.781
0.011
(1.43%)
Closed April 13 4:00PM
0.79
0.009
(1.15%)
After Hours: 6:53PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.79
Bid
0.742
Ask
0.79
Volume
283,292
0.76 Day's Range 0.82
0.2739 52 Week Range 1.75
Market Cap
Previous Close
0.77
Open
0.80
Last Trade
65
@
0.79
Last Trade Time
Financial Volume
$ 225,025
VWAP
0.794323
Average Volume (3m)
5,856,253
Shares Outstanding
14,866,400
Dividend Yield
-
PE Ratio
-1.38
Earnings Per Share (EPS)
-0.57
Revenue
-
Net Profit
-8.4M

About Monopar Therapeutics Inc

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mu... Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Monopar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MNPR. The last closing price for Monopar Therapeutics was $0.77. Over the last year, Monopar Therapeutics shares have traded in a share price range of $ 0.2739 to $ 1.75.

Monopar Therapeutics currently has 14,866,400 shares outstanding. The market capitalization of Monopar Therapeutics is $11.60 million. Monopar Therapeutics has a price to earnings ratio (PE ratio) of -1.38.

MNPR Latest News

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

WILMETTE, Ill., March 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

WILMETTE, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1625.39682539680.630.850.49993370110.69549466CS
40.0912.85714285710.70.860.49992516270.70319128CS
120.405105.1948051950.3851.730.30958562531.008098CS
260.2751.92307692310.521.730.273932611560.92666556CS
52-0.485-38.03921568631.2751.750.273917658750.92921049CS
156-4.86-86.0176991155.656.980.27396027941.0367889CS
260-23.35-96.727423363724.14480.27394504211.63094732CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
MNDRMobile health Network Solutions
$ 14.87
(45.78%)
10.66M
CNXAConnexa Sports Technologies Inc
$ 1.50
(38.89%)
16.88M
PRZOParaZero Technologies Ltd
$ 1.08
(38.46%)
12.94M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
MOTSMotus GI Holdings Inc
$ 0.2631
(-37.76%)
1.79M
CISSC3is Inc
$ 1.865
(-35.24%)
5.7M
LXEHLixiang Education Holding Company Ltd
$ 0.4325
(-33.46%)
3.12M
GVHGlobavend Holdings Ltd
$ 1.20
(-29.82%)
227.4k
SLNHSoluna Holdings Inc
$ 1.59
(-28.05%)
423.89k
SQQQProShares UltraPro Short QQQ
$ 10.89
(4.71%)
176.08M
NKLANikola Corporation
$ 0.7014
(-2.18%)
134.38M
BENFBeneficient
$ 0.09542
(38.09%)
122.81M
PXMDPaxMedica Inc
$ 0.8385
(103.59%)
114.3M
AAPLApple Inc
$ 176.55
(0.86%)
101.67M

MNPR Discussion

View Posts
TIMGZ TIMGZ 2 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173913331
👍️0
glenn1919 glenn1919 2 months ago
MNPR................................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: And let alone try to explain that sudden (late-day) circa 240% soaring by @OCEA!!! And when one searches iHub's "ALL POSTS" about OCEA, one gets ambiguous posts about "Reddit was all over it", & "One guy threw $300,000 at it". BOY, that sure explains it all!!! (BONKERS STUFF, Bro!!)
👍️0
BurgerKing82 BurgerKing82 2 months ago
If there really is 15 million shares OS...That could explain the run...Granted it is a Day 2 on a Friday,the Run fizzled
🤡 1 🤮 1
BurgerKing82 BurgerKing82 2 months ago
Wow it just crashed....idk what's next
🤡 1
TimeFades TimeFades 2 months ago
Gamma squeeze
👍️0
TimeFades TimeFades 2 months ago
Still strong
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: So am I, Dude!! NOTHING anymore makes any reasonable sense at all!!! (Their cheap FLUFF "news" of yesterday --- a mere Pre-Clinical Cancer stuff routine --- was patently UN-impressive at its core!! Yet today it soars!!)
👍️0
BurgerKing82 BurgerKing82 2 months ago
Off to a bad Start...surprised there isn't any posters,on this board...Some wild moves in either direction
🤡 1
da_stock_analyst da_stock_analyst 2 months ago
#MNPR 🔥 gap fill to $2-$3 coming? Big upside! $MNPR
👍️0
BurgerKing82 BurgerKing82 2 months ago
How many shares OS?
💩 1 🤮 1
TimeFades TimeFades 2 months ago
A lot of dumping
👍️0
TimeFades TimeFades 2 months ago
Spring tight ready for 1.5
👍️0
TimeFades TimeFades 2 months ago
Yup keeps popping off trend line
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: You yourself have posted this sentiment countless times, Boss!!! NONE of this 'Wall Street' stuff makes ANY (rational) sense at all!!!
👍️0
TheFinalCD TheFinalCD 2 months ago
yep and still goin
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: The obvious WINNER of this day!!! (And all behind a mere PHASE-1 Cancer study routine!!! How the fluck can anyone call this stuff???!!!)
👍️0
TimeFades TimeFades 2 months ago
Level 2 just switched bullish
👍️0
Awl416 Awl416 2 months ago
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: WOW!! I hear-ya behind ALL of those notes, Boss!!! (And heck, I wouldn't mind being YOUR son --- his favorite 'WHEELS' is that red VET, no doubt??? Or, he's already FLIPPED a stock by himself, & bought his OWN Vet??? Naturally!!!)
👍️0
TheFinalCD TheFinalCD 2 months ago
OH IVE BEEN BURNT BAD BEFORE

I WAS JUST TELLING MY 17YR OLD SON WHO I AM TEACHING HIM ABOUT THE MARKET

I TOLD HIM I LOST -$80K ON A PHASE 1 THAT GAPPED AND TRAPPED ME AND SO MANY OTHERS

THAT WAS BRUTAL


AND I DID IT A FEW TIMES AFTER, THEN GAVE UP ON PHASE 1 STOCKS
👍️0
Fredric Fredric 2 months ago
💪🏿
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: Well then, CONGRATS to ya, Dude!!! (& GOD BLESS!!!)
👍️0
Fredric Fredric 2 months ago
Yet n still I made money. You're expecting to much.

Just take your profits n let it be. Arguing about it isn't gonna change that.the price is going back up
N my free shares looking good

Learn to have fun. Not cry. We know companies send out pr to stop the bleeding n gain investors attention

That's why we invest.we don't marry. Everyone wants money.

Take it accordingly

Good day sir. I'm off to the next investment
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: There was NOTHING to be made in the Pre-Market, either, Clown behind this scam!!! In case you didn't know that!!!
👍️0
Fredric Fredric 2 months ago
Took original plus extra holding a few for just in case.

That's how u trade
👍️0
Fredric Fredric 2 months ago
Riding free shares
👍️0
Fredric Fredric 2 months ago
Smh 🤦🏿‍♂️ HOMEBOY

You missed the point. Keep up.. Best bet is to trade with the big boys premarket in sell at open

Or buy after hours sell at premarket or open.

Flip in the case of last minute pr

Stop looking for a reason to argue

No one will listen to your rubbish

We don't need your explanation. Just say what you gotta say n leave it at that
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: Myself, I am NOT "embarrassed", because I wasn't dumb enough to even THINK about buying this baloney sandwich (Pre-Colombian-Technology) "News". And certainly YOU --- Admiral TFCD --- weren't stupid enough either.
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: And that "bet" is now OVER, Homeboy!! (Cheap --- merely Phase-1 "news" --- & still hyping old RADIATION gadgets!!! Stay AWAY from this kind of Pre-Colombian medical "technology"!!!)
👍️0
Fredric Fredric 2 months ago
Best bet
👍️0
Invest-in-America Invest-in-America 2 months ago
MNPR: This type of LAST MINUTE news is deliberately launched as such --- as if everyone doesn't yet know that. (HA-HAAAA!! Flip it really QUICK, if ya all grabbed some of this clever PR launch!!)
👍️0
Fredric Fredric 2 months ago
We will see
👍️0
Fredric Fredric 2 months ago
I hate when halts. Its gonna one of those days

Instituionals halting to take profit

It willhold for while think we see 1000% minimum

I was hoping for 50$ runner on strength n hype.but if they keep halting it we will see 10 -15$

👍️0
TheFinalCD TheFinalCD 2 months ago
LETS SEE IF THIS HOLDS OR ANOTHER ALL DAY FADER???
👍️0
Fredric Fredric 2 months ago
👀 very
👍️0
Fredric Fredric 2 months ago
Premarket is always where the big money buy and sell.
We must trade accordingly.

This is no different. Just gott get in where we fit in
👍️0
TheFinalCD TheFinalCD 2 months ago
ITS FLYING BUT BE CAREFUL iVE LOST SO MUCH $$$$ ON PHASE 1 PREMARKET PUMPS

IM EMBARRASSED



https://www.globenewswire.com/news-release/2024/02/20/2831765/0/en/Monopar-Receives-Clearance-to-Proceed-with-First-in-Human-Phase-1-Trial-of-Novel-Radiopharmaceutical-MNPR-101-Zr-in-Advanced-Cancers.html
👍️0
Awl416 Awl416 2 months ago
Wild
👍️0
Fredric Fredric 2 months ago
Could be an interesting opener. Very good news lets see how the crowd reacts.

Some interest premarket

Might see nice jump at open with these cheap prices
👍️0
Awl416 Awl416 2 months ago
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
👍️0
subslover subslover 5 months ago
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, which is bringing together the world’s leading sarcoma specialists. Monopar’s poster presentation can be found at the following link: https://www.monopartx.com/pipeline/Camsirubicin/mnpr-201-001-clinical-trial.

Clinical Trial Results To-Date

The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts. The trial is currently ongoing and is in the fifth dose level cohort (650 mg/m2).

So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment. All patients in the fourth and fifth cohorts achieved stable disease, including the three most recently treated patients, each of whom also experienced an ~20% tumor size reduction at last study scan. One of these patients had unresectable cancer at study entry, but after the tumor size reduction, the patient became eligible for resection and underwent successful surgical removal of their cancer with clear margins.

No dose-limiting toxicity, as defined in the protocol, has been observed to-date. A medically complex patient in the 650 mg/m2 dose cohort has an ongoing left ventricular ejection fraction (LVEF) decrease that is being monitored. This patient has a BMI of 42.5, one kidney, hypertension, a long standing heart murmur, and a maternal history of heart failure. No toxicities have occurred requiring expansion of a dose cohort, and the maximum tolerated dose (MTD) has not been reached.

Camsirubicin Background

ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin was designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin to reduce cardiac damage could enable both higher and longer dosing, resulting in better efficacy and patient outcomes.
👍️0
Monksdream Monksdream 7 months ago
MNPR new 52 week low
👍️0
Monksdream Monksdream 8 months ago
MNPR new 52 week low
👍️0
subslover subslover 8 months ago
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg/m2 dose level have experienced tumor size reductions – of 18% and 20% respectively – after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction.

The Phase 1b clinical trial data is continuing to support Monopar’s dose-response hypothesis with camsirubicin. The best response seen prior to the current 650 mg/m2 dose level was at the immediately prior dose level (520 mg/m2), which was a 21% reduction in tumor size in a patient after receiving six cycles of camsirubicin treatment. This patient’s cancer was unresectable at study entry, but after the tumor size reduction, became eligible and the patient underwent successful surgical removal of their cancer with clear margins. Furthermore, all three patients at the 520 mg/m2 dose level achieved stable disease and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug.

Additionally, no drug­related cardiotoxicity has been observed in the trial to date as evaluated by the industry standard left ventricular ejection fraction (LVEF), and no toxicities have been experienced by any patient that have required expanding the size of a dose cohort. Further, 71% of camsirubicin patients have experienced no hair loss, and only approximately 14% have experienced >50% hair loss, with the remainder having low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 14% of camsirubicin patients in the Phase 1b trial have experienced mild-to-severe oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin-treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis.

ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes.

Camsirubicin Clinical Trial Design and GEIS Collaboration

The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.

Further information about this actively enrolling, open-label, dose-escalation Phase 1b clinical trial is available at www.ClinicalTrials.gov under study identifier NCT 05043649.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical­stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early­stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that additional cycles of camsirubicin treatment may result in further tumor size reduction; that the hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes; and Monopar’s plans to conduct a multi-country randomized Phase 2 clinical trial once the MTD is reached evaluating camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar. The forward-looking statements involve risks and uncertainties including, but not limited to: the camsirubicin Phase 1b trial not proving safety and efficacy at higher doses; not successfully recruiting additional patients and initiating additional clinical trial sites for the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the Company’s inability to raise sufficient funds or engage a partner to continue the camsirubicin clinical program beyond the Phase 1b clinical trial; GEIS not conducting the camsirubicin Phase 2 clinical trial; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:??

Monopar Therapeutics Inc.
Investor Relations??
Kim R. Tsuchimoto??
Chief Financial Officer??
kimtsu@monopartx.com

Follow Monopar on social media for updates:?
Twitter: @MonoparTx? LinkedIn: Monopar Therapeutics

https://www.globenewswire.com/newsroom/ti?nf=ODg4OTAzMyM1NzQxNzkxIzIxOTM4NjM=
https://ml.globenewswire.com/media/Mjc5OTExN2QtZGQwZC00YTgxLTk3OGUtMzA0ZDk0MmY4YjU1LTEyMDU0MTY=/tiny/Monopar-Therapeutics-Inc-.png

Source: Monopar Therapeutics Inc.
© 2023 GlobeNewswire, Inc.
👍️0
AJ Freely AJ Freely 8 months ago
$MNPR - 👆Up 9.9% Pre-Market/ Current Price $0.83
Monopar Provides Encouraging Camsirubicin Clinical Data Update
👍️0
retireat40 retireat40 9 months ago
1.00 right now
👍️0
Monksdream Monksdream 9 months ago
MNPR new 52 week low
👍️0
subslover subslover 10 months ago
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment

3 of 3 patients in the 520 mg/m2 cohort achieved stable disease

WILMETTE, Ill., June 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS).

Background on ASTS and Camsirubicin

ASTS is a diverse type of cancer that typically develops in the connective tissue of the body and which has metastasized (spread) or is not amenable to surgery. The average life expectancy from time of diagnosis for patients with ASTS is about 12 to 15 months. Currently, doxorubicin is the first-line standard of care treatment for most types of ASTS.

Doxorubicin is one of the most widely used cancer drugs worldwide with FDA approval in ASTS and 13 additional cancer indications. Unfortunately, although higher doses of doxorubicin are known to be more effective at treating cancer, the risk of irreversible heart damage increases with the cumulative dose and limits the lifetime amount that a patient can receive. As a result, even if patients are responding, they discontinue doxorubicin treatment typically after only 6 to 8 cycles (~6 months or less).

Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes.

Updates from Currently Enrolling Phase 1b Clinical Trial

One patient at the 520 mg/m2 dose level, unresectable at study entry, was deemed eligible for tumor resection after several cycles of camsirubicin treatment and a corresponding 21% reduction in tumor dimensions. This patient recently underwent surgical resection of the cancer.
100% of patients (3 of 3) at the fourth dose-level (520mg/m2) achieved stable disease, and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug.
Phase 1b data continue to show an improvement in median progression free survival from what was observed in the prior camsirubicin Phase 2 trial (265 mg/m2). This is supportive of our dose­-response hypothesis with camsirubicin.
Two patients are currently enrolled in the fifth dose-­level cohort (650 mg/m2), which is nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial (265mg/m2).
No drug­-related cardiotoxicity has been observed in this trial to-date as evaluated by the industry standard left ventricular ejection fraction (LVEF).
As previously reported, this trial continues to show less frequent and less severe hair loss and oral mucositis with camsirubicin compared to what has been seen in recent ASTS clinical trials with doxorubicin.
No dose limiting toxicity (DLT) has been experienced by any patient in the trial to-date.
Camsirubicin Clinical Trial Design and GEIS Collaboration

The purpose of this 3+3 dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.

Further information about this actively enrolling, open-label, dose-escalation Phase 1b clinical trial is available at www.ClinicalTrials.gov under study identifier NCT 05043649.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­-101, a late­-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-­202, an early-­stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that modifying doxorubicin to create camsirubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes; and plans to conduct a multi-country randomized Phase 2 clinical trial once the MTD is reached evaluating camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar. The forward-looking statements involve risks and uncertainties including, but not limited to: the camsirubicin Phase 1b trial not proving safety and efficacy at higher doses; not successfully recruiting additional patients and initiating additional clinical trial sites for the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the Company’s inability to raise sufficient funds or engage a partner to continue the camsirubicin clinical program beyond the Phase 1b clinical trial; GEIS not conducting the camsirubicin Phase 2 clinical trial; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:??

Monopar Therapeutics Inc.
Investor Relations??
Kim R. Tsuchimoto??
Chief Financial Officer??
kimtsu@monopartx.com

Follow Monopar on social media for updates:?
Twitter: @MonoparTx? LinkedIn: Monopar Therapeutics
👍️0
willlbone willlbone 1 year ago
$1.40 Not nice.
👍️0

Your Recent History

Delayed Upgrade Clock